TX01: EMA Validates Pediatric Plan, Targeting European Launch in 2027

A Regulatory Milestone for the Pediatric Development of TX01

The Pediatric Committee (PDCO) of the European Medicines Agency has issued a positive opinion on the Pediatric Investigation Plan (PIP) for TX01, the compound developed by THX Pharma and soon to be marketed by Exeltis for treating Niemann-Pick disease type C and Gaucher's disease in children. This opinion confirms that the development program covering qualitative, preclinical, and clinical aspects, as well as the pediatric formulation strategy, meets European regulatory requirements and validates the timeline and design of the proposed studies.

This approval of the PIP is a mandatory regulatory prerequisite for initiating a request for a Pediatric Use Marketing Authorization (PUMA) with the EMA. Exeltis plans to file this application in the first quarter of 2027.

The PUMA Procedure and Its Commercial Benefits

The PUMA is a specific authorization procedure created for drugs developed exclusively for pediatrics using active substances already approved in adults. For TX01, it combines a targeted dossier, a centralized procedure, and up to ten years of commercial market protection for pediatrics in Europe. Once granted, this marketing authorization will allow the drug to be marketed in the twenty-seven member states of the European Union, as well as in Iceland, Liechtenstein, and Norway.

Mathieu Charvériat, CEO of THX Pharma, states that this decision "validates the scientific and clinical foundations of TX01" and positions both partners "fully in line" with their roadmap. He confirms a commercial launch target in Europe by 2027, followed by subsequent rollouts in Latin America and certain Middle Eastern countries.